6 Committee comments

6 Committee comments

6.1 The Committee considered that implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes is a promising procedure that might provide benefit for many patients if further evidence supports its efficacy and safety.

6.2 In recommending further research, the Committee recognised that well‑organised prospective data collection has the potential to contribute to the evidence base, in addition to randomised controlled trials.

6.3 The Committee noted that technological developments are occurring in the design and implantation of duodenal–jejunal bypass liners, which may influence their efficacy and safety.

  • National Institute for Health and Care Excellence (NICE)